Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Microfluidics, 3D-BioPrinting & BioFabrication 2020

Microfluidics, 3D-BioPrinting & BioFabrication 2020 Agenda


Print Agenda

Tuesday, 13 October 2020

00:00

Danilo TagleKeynote Presentation

Title to be Confirmed.
Danilo Tagle, Associate Director For Special Initiatives, Office of the Director, National Center for Advancing Translational Sciences at the NIH (NCATS), United States of America

00:00

Magnetic Manipulations for Controlling 3D Neural Network Formation
Orit Shefi, Associate Professor, Head of Neuroengineering Laboratory, Faculty of Engineering and Institute of Nanotechnologies and Advanced Materials, Bar-Ilan University Israel, Israel

The ability to manipulate and direct neuronal growth has great implications in neural tissue engineering for both neuronal repair and potential medical devices. I will present our recent studies of magnetic-based manipulations  for promoting cell regeneration, controlling the organization of their extracellular environment and for directing drug delivery to the nervous system. As physical mechanical forces play a key role in neuronal morphogenesis, we use magnetic nanoparticles (MNPs) as mediators to apply forces locally on neurons throughout their migration and organization. Following incubation, the MNPs accumulated in the cells, turning the cells sensitive to magnetic stimulation. Applying magnetic fields with controlled magnetic flux densities leads to pre-designed cellular movement and to organized networks. Growing neurons loaded with MNPs under magnetic fields has affected the pattern of dendritic trees.  Moreover, we use the MNPs as mediators for shaping the 3D extracellular environment of regenerating neurons and as a platform for drug delivery, using magnetic targeting strategy to enhance therapeutic in selected cell populations. We conjugate covalently growth factors to iron oxide nanoparticles and use controlled magnetic fields to deliver the complexes to target sites. Our methods shows a controllable delivery system of biomolecules, together with integral guidance cues, presenting an emerging magneto-chemical approach for neuronal engineering and therapeutics.

00:00

Joshua EdelKeynote Presentation

Title to be Confirmed.
Joshua Edel, Professor, Imperial College London, United Kingdom

00:00

Tal DvirKeynote Presentation

Engineering Personalized Tissue Implants: From 3D Printing to Bionic Organs
Tal Dvir, Professor, Director, Laboratory for Tissue Engineering and Regenerating Medicine, Tel Aviv University, Israel

In this talk I will describe cutting-edge technologies for engineering functional tissues and organs, including the heart, brain, spinal cord and retina. I will focus on the design of new biomaterials, mimicking the natural microenvironment, or releasing biofactors to promote stem cell recruitment and tissue protection. In addition, I will discuss the development of patient-specific materials and 3D-printing of personalized vascularized tissues and organs. Finally, I will show a new direction in tissue engineering, where, micro and nanoelectronics are integrated within engineered tissues to form cyborg tissues.

00:00

Patient-Specific BBB-on-Chip Platform Enables Predictive Personalized Medicine Applications
Gad Vatine, Senior Lecturer, Ben-Gurion University of the Negev, Israel

The blood brain barrier (BBB) is a multicellular neurovascular unit (NVU) in which pericytes, astrocytes, and neurons directly interact with brain microvascular endothelial cells (BMECs). In turn, BMECs form a specialized transporter barrier created by tight junctions and polarized efflux pumps. This fine-tuned cellular architecture permits the blood-to-central nervous system (CNS) passage of crucial nutrients and metabolic molecules while prohibiting the entry of deleterious factors and most drugs. Several neurological disorders involve BBB dysfunction, creating the need to understand BBB physiology and transport mechanisms in both health and disease. Marked differences in BBB substrate specificity and transporter activity across species limit the relevance of animal models. Therefore, a human-specific BBB model is crucial to study human diseases and for the discovery of new CNS permeable drugs.

Combining iPSC and organ-on-chip technologies we developed a novel platform in which isogenic iPSC-derived iBMECs, astrocytes and neurons mimic human BBB functionality. iBMECs form a bioengineered vessel-like structure on the Organ-Chip and human astrocytes, pericytes and neurons form direct cell-to-cell interactions that mimic functionality at the level of an organ. The BBB-Chip exhibits physiologically relevant transendothelial electrical resistance and faithfully predicts BBB permeability of molecules. Whole human blood perfusion through the ‘blood vessel’ introduces another physiological interphase and demonstrates that iBMECs can protect spontaneously active neurons from cytotoxicity. Finally, genetic neurological disease modeling in the context of a functional organ reveals substrate transport variability across individual BBB, demonstrating the feasibility of this approach for predictive personalized medicine applications.

00:00

Shulamit LevenbergKeynote Presentation

Title to be Confirmed.
Shulamit Levenberg, Professor and Dean, Faculty of Biomedical Engineering, Technion Israel Institute of Technology, Israel

00:00

Title to be Confirmed.
Govind V Kaigala, Research Staff Member, IBM Research Laboratory-Zurich, Switzerland

00:00

Andrew StecklKeynote Presentation

Biofluids and Microfluidics – Point-of-Use Devices for Sensing Human Stress Biomarkers
Andrew Steckl, Gieringer Professor, Ohio Eminent Scholar, University Distinguished Research Professor, University of Cincinnati, United States of America

Hormones produced by glands in the endocrine system and neurotransmitters produced by the nervous system control many bodily functions. The concentrations of these molecules in the body are an indication of its state, hence the use of the term biomarker. Excess concentrations of biomarkers, such as cortisol, serotonin, epinephrine, dopamine, are released by the body in response to a variety of conditions - emotional state (euphoria, stress), disease, etc. The development of simple, low-cost modalities for point-of-use (PoU) measurements of biomarkers levels in various bodily fluids (blood, urine, sweat, saliva) as opposed to conventional hospital or lab settings is receiving increasing attention. The presentation starts with a review of the basic properties of primary stress-related biomarkers: origin in the body (produced as hormones, neurotransmitters or both), chemical composition, molecular weight (small/medium size molecules and polymers, ranging from ~100Da to ~100kDa), hydro- or lipo-philic nature. Next, a review of the published literature is presented regarding the concentration of these biomarkers found in several bodily fluids that can serve as the medium for determination of the condition of the subject: blood, urine, saliva, sweat and interstitial tissue fluid. The concentration of various biomarkers in most fluids covers a range of 5-6 orders of magnitude, from 100s of ng/mL (~1µM) down to a few pg/mL (sub 1pM). Mechanisms and materials for point-of-use biomarker sensors are summarized and key properties are reviewed. Illustrative examples from the literature are discussed for several sensor device categories, including capillary flow devices and microfluidic devices. Selected methods for detecting these biomarkers are reviewed, including antibody- and aptamer-based assays, electrochemical and optical detection. Finally, the presentation outlines key challenges of the field and provides a look ahead to future prospects.

00:00

GE Healthcare Life SciencesBiointelligent Manufacturing and Systems Supported by 3D Bioprinting
William Whitford, Strategic Solutions Leader, GE Healthcare Life Sciences

BioIntelligent manufacturing is a new derivative of the Industry 4.0 initiative and is of growing interest.  From the molecular perspective, the biologicalisation of processes is dependent upon advances in biochemistry, many ‘omics, and synthetic biology in animal, bacterial, and plant-based systems.  From another direction, advances in fermentation and cell culture technologies are providing a cell-based biologicalisation of processes. The harmonization of digital manufacturing principals with structures from biological systems is yielding bio-inspired materials and constructs for cell assembly, tissue and organoid engineering. 3D bioprinting supports this by enabling the production of diverse bio-based analytical and diagnostic products, including microfluidic and organ-on-a-chip in vitro tissue models for both new drug development and clinical diagnostics. 3DBP therapeutic products here include bioprinted patches, tissues and even organs. 3DBP (and personalized 3DBP) diagnostic and therapeutic materials, entities, devices and cell therapies all contribute to the elimination of old-fashioned and unsustainable product and manufacturing chemistries, toxic drug therapies, and undesirable animal-based models.

00:00

Joseph WangKeynote Presentation

Wearable Electrochemical Sensors
Joseph Wang, Chair of Nanoengineering, SAIC Endowed Professor, Director at Center of Wearable Sensors, University of California-San Diego, United States of America

00:00

Gabor ForgacsKeynote Presentation

Bioprinting is 20 Years Old: Lessons Learned
Gabor Forgacs, Professor, University of Missouri-Columbia; Scientific Founder, Organovo; CSO, Modern Meadow, United States of America

Bioprinting* has seen spectacular progress in the last two decades, both in academia and commercially. The number of researchers devoted to the topic and commercial entities in the space have grown dramatically. Publications on the topic have been multiplying exponentially. However, as with most new technologies, due to the unavoidable hype, expectations have been set unrealistically high. This talk will attempt to separate hype from reality, motivated by the desire to place the field  in the right perspective. This will be done by first briefly overviewing some of the field’s most remarkable accomplishments, using proven applications in pharmaceutic and therapeutics as illustrative examples. Finally, an unbiased view on what bioprinting realistically might accomplish in the future will be presented, as much as this is possible by someone who has been involved in the field since its birth.  

*For the purposes of this talk, bioprinting is defined as a version of 3D printing with live material, such as cells.

00:00

Title to be Confirmed.
Gary Gintant, Senior Research Fellow, Abbvie, United States of America

00:00

Title to be Confirmed.
Leanna Levine, President & CEO, ALine, Inc., United States of America

00:00

CELLINKFrom Cells to 3D Tissues: Creating Complete Workflows Using CELLINK Technologies
Jim Engström, Global Application Specialist, CELLINK

We will present how we use our 3D bioprinting technology for evaluating liver toxicity in bioprinted mini livers, comparing drug response in 2D cultures versus 3D bioprinted tumoroids and testing immuno-oncology applications with 3D bioprinted tumor models. We will also cover using light-based bioprinters to print complex vascular models. Then, we will go into how to use our x.sight™ single-cell printer for cell line development, single-cell omics and microbiome research. Last but not least, we will introduce our low-volume liquid handling system, the I-DOT, and discuss using it for dilution series in drug discovery, qPCR preparation, cell printing and tumor spheroid formation.


Agenda is not currently available
Add to Calendar ▼2020-10-13 00:00:002020-10-14 00:00:00Europe/LondonMicrofluidics, 3D-BioPrinting and BioFabrication 2020Microfluidics, 3D-BioPrinting and BioFabrication 2020 in Tel Aviv, IsraelTel Aviv, IsraelSELECTBIOenquiries@selectbiosciences.com